Sponsor

Cancer Trials Ireland

Clinical research sponsor

Published trials49
Recruiting shown6
Roles2
SourceClinicalTrials.gov

Clinical trials

49 shown
INSPIRE: INnovative SABR for Prostate Cancer All IRElandNCT07552168 · lead sponsor · 2026-04-23
RECRUITING
Precision Oncology Clinical Diagnostic Study In Primary and Metastatic Breast Cancer (PRISM)NCT07425002 · lead sponsor · 2025-11-11
RECRUITING
'SOURCE - LUNG' Stereotactic Ablative Radiation Therapy Of UltRaCEntral LUNG Tumours (SOURCE Lung)NCT04375904 · lead sponsor · 2020-12-22
RECRUITING
Breast Cancer Proteomics and Molecular HeterogeneityNCT01840293 · lead sponsor · 2013-02-01
RECRUITING
OPTIMISE Lung SABRNCT07777614 · lead sponsor · 2026-10-01
NOT_YET_RECRUITING
Neoadjuvant Trastuzumab Deruxtecan (T-DXd) With Response-directed Definitive Therapy in Early Stage HER2-positive Breast Cancer (SHAMROCK Study)NCT05710666 · lead sponsor · 2023-10-26
ACTIVE_NOT_RECRUITING
The COVID-IYON Study - Study Examining Data Pertaining to Clinical Outcomes and Organisational Responses to the 2020 SARS-CoV-2 Pandemic"NCT04581070 · lead sponsor · 2020-04-29
TERMINATED
Copanlisib in Combination With T-DM1 in Pretreated Unresectable Locally Advanced or Metastatic HER2-positive Breast CancerNCT04042051 · lead sponsor · 2019-11-12
TERMINATED
Denosumab in Combination With Enzalutamide in Progressive Metastatic Castrate-resistant Prostate Cancer and Bone Metastases.NCT03869762 · lead sponsor · 2019-01-09
TERMINATED
The Impact of the Gene Recurrence Score on Chemotherapy Prescribing in ER Positive, Lymph Node Positive Early Stage Breast CancerNCT03843346 · lead sponsor · 2017-03-16
COMPLETED
INTENSE: A Phase I/II Study of INhomogeneous Targeted Dose Escalation in Non-Small CEll Lung CancerNCT02764086 · lead sponsor · 2016-08-10
TERMINATED
Phase Ib/II Trial of coPANlisib in Combination With Trastuzumab in HER2-positive Breast Cancer. (Panther Study)NCT02705859 · lead sponsor · 2016-04-01
COMPLETED
Neo-adjuvant Abiraterone Prostate StudyNCT02160353 · lead sponsor · 2015-07-09
COMPLETED
Radium-223 in Combination With EnzalutamideNCT02225704 · lead sponsor · 2015-06-03
COMPLETED
Irish Programme for Stratified Prostate Cancer TherapyNCT03162003 · lead sponsor · 2015-02-01
COMPLETED
TAILORx Tissue BankNCT02050750 · lead sponsor · 2013-12-01
ACTIVE_NOT_RECRUITING
ABC Survey - do we Meet the Needs of Patients With Advanced Breast Cancer?NCT02051010 · lead sponsor · 2013-05-01
COMPLETED
Exosomal and Free Extracellular RNAs and Proteins as Predictive Biomarkers for HER2 Therapies in Breast CancerNCT01840306 · lead sponsor · 2012-10-12
COMPLETED
Ovarian Reserve in Premenopausal Breast CancerNCT01726322 · lead sponsor · 2012-09-01
TERMINATED
CharactHer. ICORG 12-09, V3NCT01722890 · lead sponsor · 2012-07-01
TERMINATED
A Randomized Study of TH Versus THL in First Line Treatment of HER2-positive Metastatic Breast CancerNCT01526369 · lead sponsor · 2012-02-13
COMPLETED
Circulating miRNAs.NCT01722851 · lead sponsor · 2011-05-01
COMPLETED
Single Nucleotide Polymorphism(SNP)Study. ICORG 08-40, V4NCT01726309 · lead sponsor · 2011-05-01
TERMINATED
The Myocet/Lapatinib Study. ICORG 10-03, V5NCT01495884 · lead sponsor · 2011-03-01
TERMINATED
A Phase II Neo-adjuvant Study Assessing TCH (Docetaxel, Carboplatin and Trastuzumab) and TCHL (Docetaxel, Carboplatin, Trastuzumab and Lapatinib) in HER-2 Positive Breast Cancer Patients.NCT01485926 · lead sponsor · 2010-10-01
COMPLETED
Palliative 3-Dimensional Conformal Radiation Therapy in Reducing Radiation Side Effects in Patients With Lung Cancer. ICORG 06-34NCT01176487 · lead sponsor · 2010-06-01
COMPLETED
Tarceva. ICORG 08-41NCT01721252 · lead sponsor · 2009-12-01
COMPLETED
Panobinostat, Etoposide, and Cisplatin as First-Line Therapy in Treating Patients With Extensive-Stage Small Cell Lung CancerNCT01160731 · lead sponsor · 2009-11-01
WITHDRAWN
Biomarkers of Response to Taxotere in HRPC. ICORG 08-08, V2NCT01160705 · lead sponsor · 2009-11-01
COMPLETED
3-Dimensional Conformal Radiation Therapy or Internal Radiation Therapy After Breast-Conserving Surgery in Treating Women With Stage I or Stage II Breast CancerNCT00802711 · lead sponsor · 2009-10-01
TERMINATED
A Prospective Phase II Dose Escalation Study Using IMRT for High Risk N0 M0 Prostate Cancer. ICORG 08-17NCT00951535 · lead sponsor · 2009-07-20
ACTIVE_NOT_RECRUITING
TC Avastin. ICORG 08-10, V6NCT00911716 · lead sponsor · 2008-10-01
COMPLETED
Study of Blood Samples From Patients With Malignant Melanoma, Metastatic Breast Cancer, Advanced Lung Cancer, Pancreatic Cancer, or Colorectal Cancer.NCT00974610 · lead sponsor · 2008-08-01
COMPLETED
CADY Study ICORG 08-01NCT00968682 · lead sponsor · 2008-04-01
COMPLETED
Lapatinib and Epirubicin in Treating Patients With Metastatic Breast Cancer. ICORG 06-30NCT00753207 · lead sponsor · 2007-10-01
COMPLETED
Positron Emission Tomography and Computed Tomography in Planning Treatment for Patients Undergoing 3-Dimensional Conformal Radiation Therapy for Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery. ICORG 06-35NCT00958321 · lead sponsor · 2007-03-01
TERMINATED
Bortezomib in Treating Patients With Malignant Pleural MesotheliomaNCT00513877 · lead sponsor · 2006-05-01
COMPLETED
Comparing Two Sets of Bladder-Filling Instructions in Treating Patients Undergoing Radiation Therapy For Prostate Cancer. ICORG 05-04NCT00949338 · lead sponsor · 2006-03-01
COMPLETED
Study of Blood and Urine Samples in Patients With Newly Diagnosed Localized Prostate Cancer Treated With Hormone Therapy and Radiation Therapy. ICORG 06-15NCT00955435 · lead sponsor · 2006-02-01
UNKNOWN
Hypofractionated 3-Dimensional Radiation Therapy in Treating Patients With Newly Diagnosed Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer. ICORG 99-09NCT00955175 · lead sponsor · 2000-11-01
COMPLETED
Intermittent Androgen Deprivation Therapy in the Era of AR Pathway InhibitorsNCT05974774 · collaborator · 2025-05-23
RECRUITING
Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)NCT05512364 · collaborator · 2023-12-15
RECRUITING
Sacituzumab Govitecan in Primary HER2-negative Breast CancerNCT04595565 · collaborator · 2020-10-28
ACTIVE_NOT_RECRUITING
Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the ProstateNCT04136353 · collaborator · 2020-03-31
ACTIVE_NOT_RECRUITING
Phase III Radium 223 mCRPC-PEACE IIINCT02194842 · collaborator · 2015-10-01
ACTIVE_NOT_RECRUITING
Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate CancerNCT02446444 · collaborator · 2014-03-01
ACTIVE_NOT_RECRUITING
Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate CancerNCT02446405 · collaborator · 2014-03-01
ACTIVE_NOT_RECRUITING
Male Breast Cancer: Understanding the Biology for Improved Patient CareNCT01101425 · collaborator · 2010-12-01
ACTIVE_NOT_RECRUITING
Radiation Doses and Fractionation Schedules in Non-low Risk Ductal Carcinoma In Situ (DCIS) of the BreastNCT00470236 · collaborator · 2007-06-01
UNKNOWN

Sponsor roles

lead sponsor40
collaborator9

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.